Wednesday, October 30, 2024 |
12:00 PM - 01:00 PM Eastern Daylight Time |
11:00 AM - 12:00 PM Central Daylight Time |
09:00 AM - 10:00 AM Pacific Daylight Time |
Join us in discussing disclosure considerations for public companies in the life sciences sector. Our speakers will delve into the industry’s intricacies and challenges, with a particular emphasis on the nuances relevant to biotech companies.
Topics will include:
- Background on disclosure obligations
- Materiality standard and caselaw
- Intersection of disclosure obligations and the US Food and Drug Administration
- Crafting disclosures to comply with FDA standards (overview of FDA promotional and scientific exchange standards, as applied to investor communications)
- Regulatory strategy and disclosure strategy
- Common regulatory developments that may have disclosure implications
- Partnerships, licensing arrangements, collaborations, and disclosures
CLE credit: CLE credit in CA, IL, IN, LA, NY, OH, PA, TX, and VA is currently pending approval. Credit in CT, FL, and NJ is pending approval via reciprocity.